Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/101480
Title: | Prevalence and clonal distribution of pcpA, psrP and Pilus-1 among pediatric isolates of Streptococcus pneumoniae |
Author: | Selva Jové, Laura Ciruela, Pilar Blanchette, Krystle Amo Moran, Eva del Pallarés Giner, Roman Orihuela, Carlos J. Muñoz-Almagro, Carmen |
Keywords: | Pneumococs Infeccions per pneumococs Vacuna antipneumocòccica Vacunes Vacunació dels infants Resistència als medicaments Pediatria Streptococcus pneumonia Pneumococcal Infections Pneumococcal vaccine Vaccines Vaccination of children Drug resistance Pediatrics |
Issue Date: | 25-Jul-2012 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths globally. The objective of this study was to determine the distribution and clonal type variability of three potential vaccine antigens: Pneumococcal serine-rich repeat protein (PsrP), Pilus-1, and Pneumococcal choline binding protein A (PcpA) among pneumococcal isolates from children with invasive pneumococcal disease and healthy nasopharyngeal carriers. We studied by Real-Time PCR a total of 458 invasive pneumococcal isolates and 89 nasopharyngeal pneumococcal isolates among children (total = 547 strains) collected in Barcelona, Spain, from January 2004 to July 2010. pcpA, psrP and pilus-1 were detected in 92.8%, 51.7% and 14.4% of invasive isolates and in 92.1%, 48.3% and 18% of carrier isolates, respectively. Within individual serotypes the prevalence of psrP and pilus-1 was highly dependent on the clonal type. pcpA was highly prevalent in all strains with the exception of those belonging to serotype 3 (33.3% in serotype 3 isolates vs. 95.1% in other serotypes; P<.001). psrP was significantly more frequent in those serotypes that are less apt to be detected in carriage than in disease; 58.7% vs. 39.1% P<.001. Antibiotic resistance was associated with the presence of pilus-1 and showed a negative correlation with psrP. These results indicate that PcpA, and subsequently Psrp and Pilus-1 together might be good candidates to be used in a next-generation of multivalent pneumococcal protein vaccine. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0041587 |
It is part of: | PLoS One, 2012, vol. 7, num. 7, p. e41587 |
URI: | http://hdl.handle.net/2445/101480 |
Related resource: | http://dx.doi.org/10.1371/journal.pone.0041587 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
640991.pdf | 359.03 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License